Nov-28-14 Antibe Therapeutics Reports Q2 2015 Interim Financial and Operating Results
Nov-25-14 Antibe Therapeutics Provides Update on its Acute Pain Drug ATB-352
Oct-06-14 Antibe Therapeutics Completes Single Ascending Dose Portion of ATB-346 Phase I Program
Oct-03-14 Antibe Therapeutics Reports on Results of AGM Voting
Sep-15-14 Antibe Therapeutics Commences Trading on the US OTCQX Marketplace
Sep-05-14 Antibe Therapeutics’ Founder Leads Study Identifying a Novel Mechanism for Treating Inflammatory Bowel Disease
Aug-24-14 Antibe Therapeutics Reports Q1 2015 Interim Financial and Operating Results
Jul-28-14 Antibe Therapeutics Reports Year-End Financial and Operating Results
Jul-17-14 Antibe Therapeutics Announces the Formation of its Clinical Advisory Board
Jun-26-14 Antibe Therapeutics Announces First Human Dose of ATB-346 in Phase I Clinical Trial
Jun-19-14 Antibe Therapeutics Receives Approval from Health Canada to Begin Human Clinical Testing
May-21-14 Antibe Therapeutics Announces Submission of Clinical Trial Application to Health Canada for ATB-346
May-12-14 Antibe Therapeutics Announces Addition to its Board of Directors and Grant of Options
May-05-14 CEO Letter to Shareholders
Apr-28-14 Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $4,259,958
Apr-07-14 Antibe Therapeutics Completes Second Closing of Non-Brokered Private Placement Bringing Total Proceeds to $3,925,358
Apr-01-14 Antibe Therapeutics Announces Discontinuation of Latin American Letter of Intent
Mar-31-14 Antibe Therapeutics Raises $3,015,398 in First Closing of Non-Brokered Private Placement
Mar-28-14 Antibe Therapeutics Announces Increase to Previously Announced Financing
Mar-21-14 Antibe Therapeutics Announces Non-Brokered Private Placement of $3,000,000